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It is well known that two major complications are mani- 
fested after any solid organ transplantation: rejection 
crisis due to immune conflict and infectious processes 
due to various agents (bacterial, viral, fungal). The 
question of exact and precise differentiation leads to 
adequate therapeutic decisions, because the proper 
immunosuppression would tend to preserve the rejected 
organ, but from the other hand, would interfere with the 
infection, if clinically manifested. The prediction of any 
of both complications gives a chance to overcome the 
clinical problem before its full development. Our model 
of a dynamic immunologic monitoring allows a precise 
differentiation and prognosis of the forthcoming com- 
plications after renal allotransplantation. The individuals 
studied are 54 recipients of renal allografts plus a control 
group of 24 hemodialysis patients, altogether 78. The 
methods included in this study are immunologic and 
microbiologic. The immunologic monitoring (T-helper 
and T-suppressor test and ratio-index; RBT, macrophage 
activity NBT-test, enzymatic activity SDH, alpha- 
GPDH, LDH; CIC; complement C3; NK-cell activity; 
warm and cold anti-T and anti-B antibodies; thin-needle 
aspiration biopsy morphologic analysis) is dynamically 
performed before and after transplantation and is applied 
very successfully for differentiation and prediction of 
both, rejection and infections (see our previous studies). 
The microbiologic analysis includes both, bacterial 
and viral, examinations to find out the actual cause of 
the infectious process. It is established that the following 
bacteria could be etiologic factors postoperatively: 
E. coli, Enterobacter, S. aureus, S. epidermidis, Pseudo- 
monas, Proteus, Klebsiella, E. faecalis, and Acinetobacter. 
As the bacterial origin of the infections is not our aim in 
this study, we neglect those agents: 65% of all post- 
transplantation infections. The virology analysis shows 
that 32% of all infections postoperatively are with viral 
origin: CMV, Hep. B and Hep. C virus, influenza virus, 
HIV The other 3% of the infections are from fungal 
origin (also out of our research plans at the moment). 
The results show that 21 cases (32%) are with viral 
infections: CMV - 8 (38%), HepB - 4 (19%), HepC -3 
(14%), Influenza - 5 (24%), HIV - 1 (5%), but 4 cases 
have a mixed infection: CMV+Influenza (2), CMV+ 
Hep+HIV (l), Influenza+Hep (1). The duration of the 
viral complications is 1.5 times longer than the bacterial 
ones. Two of the recipients with viral infections have a 
lethal issue: 1 with HIV (mixed with CMV+Hep) and 
1 with CMV (mixed with Influenza). Over 80% of all 
viral complications are clinically manifested in patients 
treated with cyclosporine and under 20% are in recipients 
without current cyclosporine therapy. The hemodialysis 
patients (24) show a prevalence of Hep-infections and 
2/3 of the cases are HepC. The immunologic monitoring 
definitely helps to predict and differentiate the immune 
conflict and rejection, as one of the two major com- 
plications after renal allotransplantation, and the 
infection, as a second one. From the other hand, the viral 
processes and the manifested immunodefficiency, alone 
or in combination, require a thorough analysis, exact 
diagnosis and individual therapeutic scheme. 
Early measles vaccination in bone marrow transplant 
(BMT) recipients 
C. M. Machado, L. M. Sumita, I. F da Rocha, 
C. S. Pannuti, Vauf de Souza 
Virology Laboratory, Institute of Tropical Medicine, 
and BMT Program, Discipline of Hematology, 
University of Stio Paul0 Medical School, Brazil 
Measles vaccination has been recommended after the 
second year following BMT, for patients not receiving 
immunosuppression. During a measles outbreak that 
irrupted in the city of SBo Paulo in 1997, we started 
measles vaccination for all patients after the first year of 
transplantation and conducted a prospective trial to 
evaluate the safety, effectiveness and sustained 
immunity after early measles vaccination. Patients 
received attenuated virus measles vaccination on day 
+365. Measles antibodies were detected by ELISA in 
serum samples taken on months 0,2,6,12 and 24 after 
vaccination. Thirty seven BMT recipients (5 ABMT, 
32 ALO) were evaluated. No severe or moderate 
adverse reactions was noted. Nine patients (24.3%) were 
susceptible (IgG 2 100 mUI/mL) at vaccination and all 
of them seroconverted. In patients considered immune 
at vaccination, a four fold rise in IgG titers was observed 
in only one of 24 patients (4.1%) with IgG ~200 
mUI/mL as compared to three of 4 patients (75%) with 
lOOcIgG<200 mUI/mL (p=O.O012), supporting that 
higher titers avoid wild or vaccine virus replication. 
Survival analysis showed a 96.4%, 86% and 60.2% 
probabilities of sustained measles immunity at 12,18 and 
24 months after early measles vaccination, respectively. 
Patients with IgG titers between 200 and 500 mUI/mL 
at vaccination were less likely to retain measles 
immunity 12 months after vacciantion as compared to 
those with IgG titers 2500 mUI/mL (p=O.Ol). The 
former patients should be screened more frequently for 
measles antibodies during follow-up. We concluded that 
measles vaccination on day +365 is safe and effective in 
BMT recipients and can be recommended in countries 
that did not achieved measles elimination. Booster doses 
of measles vaccine should be recommended only in 
patients with IgG titers <200mUI/mL. 
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Objective: Non myeloablative conditioning regimen 
(NMCR) for AHSCT have been developed to reduce 
procedure-related toxicity. The aim of this approache is 
to extend indications of AHSCT to patients (pts) who 
are not eligible previously for high dose chemotherapy 
or total body irradiation. We describe infectious mor- 
bidity related to this new procedure in our unit in a 
retrospective study. 
Results: 45 AHSCT with NMCR were performed in our 
unit between 1997 to 2001,32 males, 13 females, with a 
median age of 48 years (range 18-62). Hematologic 
diagnosis were 8 AL, 12 MM, 2 CML, 5 NHL, 3 MDS, 6 
Hodgkin diseases, 3 CLL, 6 solid tumors. Engraftment 
was observed in all pts with a median of 21 days (range 
12119) for PNN >0.5 g/l, and 18 days (range O-201) for 
platelets >50 g/l. Ten pts received donor lymphocyte 
infusions (DLI). Nineteen pts (48.7%) presented acute 
GVHD: 7 without any DLI, 4 before DLI and 8 after 
DLI (2 grade 1,7 grade 2,4 grade 3 and 2 grade 4). 
Nineteen pts (42%) presented 39 infections : 1 episode, 
II = 7; 2 episodes, II = 7; 3 episodes, it = 3; 4 episodes, n= 1; 
5 episodes, y1= 1. Twenty two infections (56.5 %) occured 
in 13 pts during 3 months post transplant : 18 septi- 
cemia (12 Gram-negative bacilli, 5 Gram-positive cocci, 
one yeast), 1 septic chock without documentation, 2 
cytomegalovirus (CMV) infections, 1 zoster. Only 4 of 
these infections occured after engraftment (3 bacterial 
septicemia and 1 CMV disease). The pt with fungal 
septicemia died before engraftment. We observed 17 late 
infections (43.5%) in 11 pts : 3 septicemia, 1 septic chock 
without documentation, 2 CMV diseases, 6 probable 
invasive aspergillosis, 1 zoster, 1 Campylobacter colitis, 
1 Staphylococcus aureus pneumonia, 1 EBV lymphoma 
and 1 enterovirus encephalitis. Overall, bacterial in- 
fections were observed in 56% of cases, viral in 20% and 
fungal in 18%. No infection occured in 26 pts (58%). 
Five pts with hematologic malignancy relapse pre- 
sented a probable invasive aspergillosis. 
Twenty eight pts died (62%) 16 in relapse, 9 (32%) 
with infection : 1 fungal septicemia, 1 viral encephalitis, 
1 hepatitis, 6 invasive aspergillosis. 
Conclusion: Most of infections observed after AHSCT 
with NMCR were bacterial in our experience. 
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Aim: To describe the results of our strategies of pre- 
vention and treatment of infectious episodes during the 
neutropenic phase in HSCT Rc. 
Materials and methods : Total number of HSCT 417; 
number of patients (pts): 388; mean age: 33.9 (l-70); 
female: 256 (61%); hematological diseases: 247 (59%) 
solid tumors: 168 (40%) others 2; autologous (AU) 
314 (75%) allogeneic (AL) 103 (25%): related 89 (85%, 
haploidentical 3-2%) non-related 14 (13%): bone 
marrow 10, umbilical cord blood 4. Mean engraftment 
days: 12.8 (0-48).Weekly surveillance cultures (WSC) 
were done: anterior nares swab: detection (dt) of 
methicillin-resistant (R) Staphylococcus sp, penicillin-R 
pneumococci and Aspergillus sp, mouthwash: dt of 
Candida sp, penicillin-R Streptococcus sp and stool: dt 
of multidrug-R aerobic gram-negative bacilli (AGNB), 
vancomycin-R Enterococcus and Candida sp. Routinely 
selective gastrointestinal decontamination for AGNB 
and antifungal prophylaxis were not done. Fluconazol 
(FLU) was used only in pts with non-C. krusei colon- 
ization detected by WSC. The initial empirical treatment 
for neutropenia and fever was ceftazidime plus amikacin. 
The febrile episodes were defined according to the guide- 
lines of the Immunocompromised Host Society (1990). 
Results: 434 febrile episodes were detected: a) microbio- 
logically defined infection 150 (34.5%): mono or poly- 
microbial bacteremia (B) 63, fungemia (F) 2; site of 
infection (SI) with B 37 and with F 3; bacterial SI without 
B 55 and fungal SI without F 6; b) clinically defined 
infection 90 (21%) and c) possible infection 194 (45 %); 
there were 11 pts without fever. Isolated micro- 
organisms: 121 from 105 B and F,AGNB 52 (43%) with 
46 (85%) Enterobacteriaceae, gram-positive cocci 53 
(44%) with 41(77%) Staphylococcus sp, others 11(9%) 
and non-C. albicans 5 (4%). Nine pts had polymicrobial 
B and 7 more than one episode of B. The most frequent 
sites of infections with or without microbiological docu- 
mentation were: urinary tract 51(25%), lungs 48 (23%) 
skin and soft tissues 31 (15%) anal 25 (12%) and 
catheter 21 (lO%).Two hundred thirty colonized pts 
(55%) received FLU prophylaxis and 136 pts (33%) 
empirical amphotericin B (desoxycholate 119, liposomal 
28). Related transplant mortality was 10% (38/388), 
AU 8% (25/314), Al 13% (13003)and associated with 
documented infection 2% (7/388). 
Conclusions: (1) The use of FLU was avoided in 45 % of 
the pts, with the benefit of decreasing toxicity and costs. 
(2) All fungemias were by non-C.albicans, probably due 
to the previous overuse of FLU. (3) The same empirical 
antibiotic treatment has been used from the beginning 
of the program without emergence of R strains. (4) 
Mortality associated to documented infection was low, 
supporting our strategies of prevention and treatment. 
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Background: Transmission of bacterial infections from a 
donor to multiple recipients may occur in the setting of 
